1. Home
  2. ESNT vs IMVT Comparison

ESNT vs IMVT Comparison

Compare ESNT & IMVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Essent Group Ltd.

ESNT

Essent Group Ltd.

HOLD

Current Price

$65.79

Market Cap

5.9B

Sector

Finance

ML Signal

HOLD

Logo Immunovant Inc.

IMVT

Immunovant Inc.

HOLD

Current Price

$25.25

Market Cap

5.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ESNT
IMVT
Founded
2008
2018
Country
Bermuda
United States
Employees
N/A
N/A
Industry
Property-Casualty Insurers
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.9B
5.3B
IPO Year
2013
N/A

Fundamental Metrics

Financial Performance
Metric
ESNT
IMVT
Price
$65.79
$25.25
Analyst Decision
Buy
Buy
Analyst Count
5
9
Target Price
$68.00
$25.29
AVG Volume (30 Days)
648.5K
2.0M
Earning Date
02-13-2026
02-05-2026
Dividend Yield
1.89%
N/A
EPS Growth
N/A
N/A
EPS
6.87
N/A
Revenue
$1,263,558,000.00
N/A
Revenue This Year
$3.87
N/A
Revenue Next Year
$1.55
N/A
P/E Ratio
$9.56
N/A
Revenue Growth
2.04
N/A
52 Week Low
$51.61
$12.72
52 Week High
$67.09
$27.69

Technical Indicators

Market Signals
Indicator
ESNT
IMVT
Relative Strength Index (RSI) 63.63 52.14
Support Level $65.41 $26.35
Resistance Level $66.11 $27.64
Average True Range (ATR) 0.99 1.41
MACD 0.01 -0.15
Stochastic Oscillator 73.21 54.10

Price Performance

Historical Comparison
ESNT
IMVT

About ESNT Essent Group Ltd.

Essent Group Ltd serves the housing finance industry by providing private mortgage insurance, reinsurance, risk management products, title insurance, and settlement services to mortgage lenders, borrowers, and investors to support homeownership. It provides credit protection to lenders and mortgage investors by covering a portion of the unpaid principal balance of a mortgage and certain related expenses in the event of a default. By providing capital to mitigate mortgage credit risk, the company allows lenders to make additional mortgage financing available to prospective homeowners.

About IMVT Immunovant Inc.

Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The company operates in a single operating segment, which includes all activities related to the research, development and manufacturing of its product candidates.

Share on Social Networks: